Meanwhile, the nanoparticles conjugated with anti-HER2 affibodies induce the selective binding of nanoparticles to HER2-overexpressing breast cancer cells through an antibody-to-antigen pattern (21), suggesting that the nanoparticles of 131I-PLGA modified by rhTSH, as an antigen, were selectively bound to TSHR-expressing thyroid cancer cells in an antibody-to-antigen manner. The gene discussed is ERBB2; the disease is breast carcinoma.